Latest Biotech News

Eli Lilly agreed to buy Centessa Pharmaceuticals for about $6.3 billion up front, plus contingent value rights that could add roughly $1.5 billion tied to FDA approvals for Centessa’s orexin...

Biogen agreed to acquire Apellis Pharmaceuticals for about $5.6 billion, adding two marketed immunology assets and bolstering its late-stage pipeline. The companies’ deal values Apellis at $41 per...

Otsuka Pharmaceutical agreed to acquire Transcend Therapeutics for $1.22 billion to advance a neuroplastogen approach in posttraumatic stress disorder (PTSD). Transcend’s lead asset, TSND-201, is...

The FDA flagged more than 70 cases of severe liver injury and eight deaths associated with Amgen’s autoimmune treatment Tavneos, prompting renewed scrutiny of the drug’s risk profile. In its...

Braveheart Bio reported positive results from an open-label randomized Phase 2 dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy (oHCM). Data presented at the...

Simcere Pharmaceutical Group’s monoclonal antibody rademikibart (CBP-201) met the primary endpoint in a Chinese Phase 3 study in adults and adolescents with moderate to severe atopic dermatitis....

Innovent Biologics reported that efdamrofusp alfa (IBI-302) met the primary endpoint in its Phase 3 Star trial in neovascular age-related macular degeneration (nAMD). The Suzhou-based company said...

Semarion raised $3.8 million to scale its cell assay technology for drug discovery. The company’s SemaCyte platform is designed to convert adherent cell models into assay-ready, barcoded reagents,...

Baebies received 510(k) clearance and a CLIA waiver for a triplex respiratory test on its Finder point-of-care instrument, enabling detection of influenza A, influenza B, and SARS-CoV-2. The...

Merck signed a collaboration with Infinimmune to discover new therapeutic antibodies using the startup’s AI-driven platform built on human immune cell datasets. Under the deal, Merck could pay up...

Novo Nordisk has launched a subscription program for Wegovy, letting cash-paying patients buy 3-month, 6-month, or yearlong bundles for injections and oral formulations, the company said. The...

Colorado-based Ambrosia Biosciences secured $100 million in new financing to develop an oral small-molecule GLP-1 program. The funding supports continued preclinical and clinical development...

Novo Nordisk and United Biotechnology’s next-generation triple incretin therapy outperformed semaglutide in a phase II trial, signaling intensifying competition in GLP-1 obesity and diabetes. The...

Innovent Biologics reported that efdamrofusp alfa (IBI-302) met the primary endpoint in its phase III Star trial for neovascular age-related macular degeneration (nAMD). The Suzhou-based company...

Biogen agreed to acquire Apellis Pharmaceuticals for about $5.6 billion, gaining two commercial immunology assets and strengthening its pipeline ahead of planned launches. The transaction includes...

Eli Lilly is expanding its AI-driven discovery footprint through a multibillion-dollar expansion of its collaboration with Insilico Medicine. The updated deal structure is reported as $115 million...

Braveheart Bio reported positive results from an open-label randomized phase II dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy. Results presented at the...

Viridian Therapeutics’ elegrobart phase III readout in active thyroid eye disease met its primary endpoint, but the stock fell sharply after investors questioned the overall commercial positioning...

FDA reviewers raised manufacturing and quality-control concerns that could make it prohibitively expensive to scale bespoke gene editing treatments for children with rare diseases, according to...

Rocket Pharmaceuticals received FDA approval for Kresladi, a gene therapy for leukocyte-adhesion deficiency type 1 (LAD-1), according to reporting from MedCity News. The approval is framed as the...